Resverlogix Announces Lead Drug Apabetalone Publication and Presentation at BIO International 2017 Jun 5, 2017
First Clinical Trial Of Embryonic Stem Cells Is Set To Treat Parkinson’s Disease And Blindness Jun 2, 2017 Life Science
Naturally Splendid Signs German Based Distributor and Ships Initial Purchase Order Jun 1, 2017 Life Science
Cancer Screening Tie-up: Hong Kong’s Cirina Merges With GRAIL, an Illumina Spin-Out Jun 1, 2017 Life Science
Resverlogix To Host Epigenetics Focused Symposium At The ERA-EDTA Congress in Madrid, Spain Jun 1, 2017 Life Science
Resverlogix Receives Approval From Health Canada To Proceed With Fabry Disease Clinical Trial With Lead Compound Apabetalone May 30, 2017 Life Science
Naturally Splendid announces LOI with Ambarii Corp to Distribute CBD Tablets in Japan and South Korea May 30, 2017 Life Science
Recent Publication and Patent Application Referencing Apabetalone Support its Continued Development and Success May 23, 2017 Life Science
DelMar Pharmaceuticals Announces Third Quarter Fiscal Year 2017 Financial Results May 19, 2017 Life Science
Resverlogix Receives Approval From The FDA Cardiovascular and Renal Division To Proceed With A Requested Apabetalone Clinical Trial May 15, 2017 Life Science
DelMar Formalizes Collaboration with PRA Health Sciences for Phase 3 Trial of VAL-083 in Recurrent Glioblastoma Multiforme (GBM) May 12, 2017 Life Science
DelMar Presents New Mechanism of Action Data for its Lead Agent VAL-083 in Temozolomide-Resistant Glioblastoma Multiforme (GBM) at the World Federation of Neuro-Oncology Societies (WFNOS) May 9, 2017 Life Science
